

10/27/04

=> s 14 and prd < sept 1998
L8 22 L4 AND PRD < SEPT 1998

=> d abs bib fhitr 1-22

L8 ANSWER 1 OF 22 USPTATFULL on STN

AB The present invention relates to new new piperidyl- or
piperazinyl-substituted dihydro-2H-1-benzopyran derivatives compound
having the formula (I) ##STR1##

wherein

X is N or CH;

Y is NR.sub.2CH.sub.2, CH.sub.2NR.sub.2, NR.sub.2CO, CONR.sub.2,
NR.sub.2SO.sub.2 or NR.sub.2CONR.sub.2

wherein R.sub.2 is H or C.sub.1-C.sub.6 alkyl;

R.sub.1 is H, C.sub.1-C.sub.6 alkyl or C.sub.3-C.sub.6 cycloalkyl;

R.sub.3 is C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl or
(CH.sub.2).sub.n-aryl,

wherein aryl is phenyl or a heteroaromatic ring containing one or two
heteroatoms selected from N, O and S and which may be mono- or
di-substituted with R.sub.4 and/or R.sub.5;

and n is 0-4;

as (R)-enantiomers, (S)-enantiomers or a racemate in the form of a free
base or a pharmaceutically acceptable salt or solvate thereof, a process
for their preparation, pharmaceutical compositions containing said
therapeutically active compounds and to the use of said active
compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:203965 USPTATFULL

TI Substituted chroman derivatives

IN Berg, Stefan, Ekero, SWEDEN

Nylof, Martin, Sodertalje, SWEDEN

Ross, Svante, Sodertalje, SWEDEN

Thorberg, Seth-Olov, Strangnas, SWEDEN

PI US 2004157857 A1 20040812

AI US 2003-714577 A1 20031113 (10)

RLI Division of Ser. No. US 2002-285743, filed on 1 Nov 2002, GRANTED, Pat.
No. US 6670359 Division of Ser. No. US 1998-171570, filed on 21 Oct
1998, GRANTED, Pat. No. US 6479497 A 371 of International Ser. No. WO
1998-SE1603, filed on 9 Sep 1998, UNKNOWN

PRAI SE 1997-3377 19970918

<--

DT Utility

FS APPLICATION

LREP WHITE & CASE LLP, PATENT DEPARTMENT, 1155 AVENUE OF THE AMERICAS, NEW
YORK, NY, 10036

CLMN Number of Claims: 30

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 2048

10/714,577

10/27/04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 221185-02-0P

(preparation of substituted chroman derivs. and their effects at the h5-HT1B receptor)

RN 221185-02-0 USPATFULL

CN 2,6-Piperazinedione, 1-[(3S)-3-[bis(phenylmethyl)amino]-3,4-dihydro-2H-1-benzopyran-5-yl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L8 ANSWER 2 OF 22 USPATFULL on STN

AB The present invention relates to new new piperidyl- or piperazinyl-substituted dihydro-2H-1-benzopyran derivatives compound having the formula (I) ##STR1##

wherein

X is N or CH;

Y is NR.sub.2CH.sub.2, CH.sub.2NR.sub.2, NR.sub.2CO, CONR.sub.2, NR.sub.2SO.sub.2 or NR.sub.2CONR.sub.2

wherein R.sub.2 is H or C.sub.1-C.sub.6 alkyl;

R.sub.1 is H, C.sub.1-C.sub.6 alkyl or C.sub.3-C.sub.6 cycloalkyl;

R.sub.3 is C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl or (CH.sub.2).sub.n-aryl;

wherein aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted with R.sub.4 and/or R.sub.5;

and n is 0-4;

as (R)-enantiomers, (S)-enantiomers or a racemate in the form of a free base or a pharmaceutically acceptable salt or solvate thereof, a process for their preparation, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AN 2003:146809 USPATFULL

10/714,577

10/27/04

TI Substituted chroman derivatives
IN Berg, Stefan, Ekero, SWEDEN
Nylof, Martin, Sodertalje, SWEDEN
Ross, Svante, Sodertalje, SWEDEN
Thorberg, Seth-Olov, Strangnas, SWEDEN
PI US 2003100556 A1 20030529
US 6670359 B2 20031230
AI US 2002-285743 A1 20021101 (10)
RLI Division of Ser. No. US 1998-171570, filed on 21 Oct 1998, GRANTED, Pat.
No. US 6479497 A 371 of International Ser. No. WO 1998-SE1603, filed on
9 Sep 1998, UNKNOWN
PRAI SE 1997-3377 19970918 <--
DT Utility
FS APPLICATION
LREP WHITE & CASE LLP, PATENT DEPARTMENT, 1155 AVENUE OF THE AMERICAS, NEW
YORK, NY, 10036
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 2041
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 221185-02-0P
(preparation of substituted chroman derivs. and their effects at the h5-HT1B
receptor)
RN 221185-02-0 USPATFULL
CN 2,6-Piperazinedione, 1-[(3S)-3-[bis(phenylmethyl)amino]-3,4-dihydro-2H-1-
benzopyran-5-yl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L8 ANSWER 3 OF 22 USPATFULL on STN
AB The present invention relates to indole and 2,3-dihydroindole
derivatives having formula (I) ##STR1##

or any of its any of its enantiometers or any mixture thereof, or an
acid addition salt thereof, wherein A, R.sup.1, R.sup.2, R.sup.3, W, X,
Y and Z are as described in the description. The compounds are potent
serotonin reuptake inhibitors and have 5-HT.sub.1A receptor antagonistic
activity.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:24207 USPATFULL
TI Indole and 2,3-dihydroindole derivatives, their preparation and use

10/714,577

10/27/04

IN Moltzen, Ejner Knud, Gentofte, DENMARK
Perregaard, Jens Kristian, Jaegerspris, DENMARK
Mikkelsen, Ivan, Koge, DENMARK
Smith, Garrick Paul, Valby, DENMARK
PA H. Lundbeck A/S, Valby-Copenhagen, DENMARK (non-U.S. corporation)
PI US 2003018050 A1 20030123
US 6727263 B2 20040427
AI US 2002-223046 A1 20020816 (10)
RLI Division of Ser. No. US 2000-491204, filed on 25 Jan 2000, GRANTED, Pat.
No. US 6476035 Continuation of Ser. No. WO 1998-DK36, filed on 20 Jul
1998, UNKNOWN
PRAI DK 1997-892 19970725 <--
US 1997-53713P 19970725 (60) <--
DT Utility
FS APPLICATION
LREP DARBY & DARBY P.C., Post Office Box 5257, New York, NY, 10150-5257
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 220251-33-2P
(preparation of indole and 2,3-dihydroindole derivs. as potent serotonin
reuptake inhibitors and 5-HT1A receptor antagonists)
RN 220251-33-2 USPATFULL
CN 1H-Indole, 6-chloro-3-[2-[4-(6-chloro-3,4-dihydro-2,2-dimethyl-2H-1-
benzopyran-8-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 22 USPATFULL on STN
AB The present invention relates to new new piperidyl or
piperazinyl-substituted dihydro-2H-1-benzopyran derivatives compound
having the formula (I) ##STR1##

wherein

X is N or CH;

Y is NR.sub.2CH.sub.2, CH.sub.2NR.sub.2, NR.sub.2CO, CONR.sub.2,
NR.sub.2SO.sub.2 or NR.sub.2CONR.sub.2 wherein R.sub.2 is H or
C.sub.1-C.sub.6 alkyl;

R.sub.1 is H, C.sub.1-C.sub.6 alkyl or C.sub.3-C.sub.6 cycloalkyl;

R.sub.3 is C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl or
(CH.sub.2).sub.n-aryl,

wherein aryl is phenyl or a heteroaromatic ring containing one or two

10/27/04

heteroatoms selected from N, O and S and which may be mono- or di-substituted with R.sub.4 and/or R.sub.5;

and n is 0-4;

as (R)-enantiomers, (S)-enantiomers or a racemate in the form of a free base or a pharmaceutically acceptable salt or solvate thereof, a process for their preparation, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:297590 USPATFULL
TI Substituted chroman derivatives
IN Berg, Stefan, Ekerö, SWEDEN
Nylof, Martin, Sodertalje, SWEDEN
Ross, Svante, Sodertalje, SWEDEN
Thorberg, Seth-Olov, Strangnas, SWEDEN
PA Astrazeneca AB, SWEDEN (non-U.S. corporation)
PI US 6479497 B1 20021112
WO 9914212 19990325
AI US 1998-171570 19981021 (9)
WO 1998-SE1603 19980909
19981021 PCT 371 date
PRAI SE 1997-3377 19970918 <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Desai, Rita
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1920


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 221185-02-0P

(preparation of substituted chroman derivs. and their effects at the h5-HT1B receptor)

RN 221185-02-0 USPATFULL
CN 2,6-Piperazinedione, 1-[(3S)-3-[bis(phenylmethyl)amino]-3,4-dihydro-2H-1-benzopyran-5-yl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L8 ANSWER 5 OF 22 USPATFULL on STN

10/714,577

10/27/04

AB The present invention relates to indole and 2,3-dihydroindole derivatives having formula (I) ##STR1##

or any of its any of its enantiomers or any mixture thereof, or an acid addition salt thereof, wherein A, R.sub.1, R.sub.2, R.sub.3, W, X, Y and Z are as described in the description. The compounds are potent serotonin reuptake inhibitors and have 5-HT.sub.1A receptor antagonistic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:290944 USPATFULL
TI Indole and 2,3-dihydroindole derivatives, their preparation and use
IN Moltzen, Ejner Knud, Toftekaersvej 29, Gentofte, DENMARK DK-2820
Perregaard, Jens Kristian, Bautahøjvej 44, Jaegerspris, DENMARK DK-3630
Mikkelsen, Ivan, Strandvejen 97, Koge, DENMARK DK-4600
Smith, Garrick Paul, AEBlehaven 10, Valby, DENMARK DK-2500
PI US 6476035 B1 20021105
AI US 2000-491204 20000125 (9)
RLI Continuation of Ser. No. WO 1998-DK336, filed on 20 Jul 1998
PRAI DK 1997-892 19970725 <--
US 1997-53713P 19970725 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Bernhardt, Emily
LREP Darby & Darby
CLMN Number of Claims: 16
ECL Exemplary Claim: 1,12
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1322


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 220251-33-2P

(preparation of indole and 2,3-dihydroindole derivs. as potent serotonin reuptake inhibitors and 5-HT_{1A} receptor antagonists)

RN 220251-33-2 USPATFULL

CN 1H-Indole, 6-chloro-3-[2-[4-(6-chloro-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-8-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 6 OF 22 USPATFULL on STN

AB Disclosed are compounds of the formula: ##STR1##

or the pharmaceutically acceptable acid addition salts thereof wherein:

R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are the same or different and represent hydrogen, halogen, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.4 alkylthio, hydroxy, amino, mono- or di(C.sub.1-C.sub.6)alkylamino, cyano, nitro, trifluoromethyl or trifluoromethoxy; and

10/714,577

10/27/04

X is oxygen, a bond, C.sub.1-C.sub.2 alkylene, or methyleneoxy,


which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:186135 USPATFULL
TI 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands
IN Tran, Jennifer N., Branford, CT, UNITED STATES
Thurkauf, Andrew, Danbury, CT, UNITED STATES
PA Neurogen Corporation, Branford, CT (U.S. corporation)
PI US 2002099056 A1 20020725
US 6486164 B2 20021126
AI US 2001-27150 A1 20011220 (10)
RLI Continuation of Ser. No. US 2001-761048, filed on 16 Jan 2001, PATENTED
Continuation of Ser. No. US 1999-343309, filed on 30 Jun 1999, PATENTED
PRAI US 1998-91250P 19980630 (60) <--
DT Utility
FS APPLICATION
LREP Steven J. Sarussi, McDonnell Boehnen Hulbert & Berghoff, 32nd Floor, 300
S. Wacker Drive, Chicago, IL, 60606
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 672

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 253689-50-8P, 1-(Chroman-6-yl)-4-(4-methylbenzyl)piperazine
(preparation of (arylalkylpiperazinyl)benzodioxane and
(arylalkylpiperazinyl)chroman derivs. as subtype-specific dopamine
receptor ligands)
RN 253689-50-8 USPATFULL
CN Piperazine, 1-(3,4-dihydro-2H-1-benzopyran-6-yl)-4-[(4-
methylphenyl)methyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 22 USPATFULL on STN

AB The present invention relates to new piperidinyl- or piperazinyl-substituted-3,4-dihydro-2H-1-benzopyran derivatives having formula (I) wherein X is N or CH; Y is NR.sub.2CH.sub.2, CH.sub.2NR.sub.2, NR.sub.2CO, CONR.sub.2 or NR.sub.2SO.sub.2 wherein R.sub.2 is H or C.sub.1-C.sub.6 alkyl; R.sub.1 is H, C.sub.1-C.sub.6 alkyl or C.sub.3-C.sub.6 cycloalkyl; R.sub.3 is C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl or (CH.sub.2).sub.n-aryl, wherein aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted; n is 0-4; R.sub.9 is C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl,

10/714,577

10/27/04

OCF.sub.3, OCHF.sub.2, OCH.sub.2F, halogen, CONR.sub.6R.sub.7, CN, CF.sub.3, OH, C.sub.1-C.sub.6 alkoxy, NR.sub.6R.sub.7, SO.sub.3CH.sub.3, SO.sub.3CF.sub.3, SO.sub.2NR.sub.6R.sub.7, an unsubstituted or substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from N and O, wherein the substituent(s) is(are) C.sub.1-C.sub.6 alkyl; or COR.sub.8; wherein R.sub.6, R.sub.7 and R.sub.8 are as defined above, as (R)-enantiomers, (S)-enantiomers or racemates in the form of a free base or pharmaceutically acceptable salts or solvates thereof, a process for their preparation, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AN 2002:109037 USPATFULL
TI Substituted chroman derivatives
IN Berg, Stefan, Ekero, SWEDEN
Linderberg, Mats, Sodertalje, SWEDEN
Ross, Svante, Sodertalje, SWEDEN
Thorberg, Seth-Olov, Strangnas, SWEDEN
Ulff, Bengt, Sodertalje, SWEDEN
PA AstraZeneca AB, Sodertalje, SWEDEN (non-U.S. corporation)
PI US 6387899 B1 20020514
WO 9914213 19990325
AI US 1998-171572 19981021 (9)
WO 1998-SE1604 19980909
19981021 PCT 371 date
PRAI SE 1997-3378 19970918 <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Ramsuer, Robert W.
LREP White & Case LLP
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1937

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 221185-10-0P
(preparation of substituted chroman derivs.)
RN 221185-10-0 USPATFULL
CN 2H-1-Benzopyran-8-carboxylic acid, 3-[bis(phenylmethyl)amino]-3,4-dihydro-5-(4-methyl-1-piperazinyl)-, methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/27/04



L8 ANSWER 8 OF 22 USPTAFULL on STN

AB The present invention relates to new piperidinyl- or piperazinyl-substituted-3,4-dihydro-2H-1-benzopyran derivatives having the formula I ##STR1##

wherein

X is N or CH;

Y is NR.sub.2CH.sub.2, CH.sub.2NR.sub.2, NR.sub.2CO, CONR.sub.2 or NR.sub.2SO.sub.2

wherein R.sub.2 is H or C.sub.1-C.sub.6 alkyl;

R.sub.1 is H, C.sub.1-C.sub.6 alkyl or C.sub.3-C.sub.6 cycloalkyl;

R.sub.3 is C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl or (CH.sub.2).sub.n-aryl,

wherein aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted;

n is 0-4;

R.sub.9 is C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl, OCF.sub.3, OCHF.sub.2, OCH.sub.2F, halogen, CONR.sub.6R.sub.7, CN, CF.sub.3, OH, C.sub.114 C.sub.6 alkoxy, NR.sub.6R.sub.7, SO.sub.3CH.sub.3, SO.sub.3CF.sub.3, SO.sub.2NR.sub.6R.sub.7, an unsubstituted or substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from N and O, wherein the substituent(s) is(are) C.sub.1-C.sub.6 alkyl; or COR.sub.8; wherein R.sub.6, R.sub.7 and R.sub.8 are as defined above,

as (R)-enantiomers, (S)-enantiomers or racemates in the form of a free base or pharmaceutically acceptable salts or solvates thereof, a process for their preparation, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy.

10/714,577

10/27/04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:102640 USPATFULL
TI Intermediates in the preparation of substituted chroman derivatives
IN Berg, Stefan, Ekero, SWEDEN
Linderberg, Mats, Sodertalje, SWEDEN
Ross, Svante, Sodertalje, SWEDEN
Thorberg, Seth-Olov, Strangnas, SWEDEN
Ulff, Bengt, Sodertalje, SWEDEN
PA AstraZeneca AB, Sodertalje, SWEDEN (non-U.S. corporation)
PI US 6384225 B1 20020507
AI US 2000-653552 20000831 (9)
RLI Division of Ser. No. US 171572
PRAI SE 1997-3378 19970918 <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Ramsuer, Robert W.
LREP White & Case LLP
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1840

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 221185-10-0P

(preparation of substituted chroman derivs.)

RN 221185-10-0 USPATFULL

CN 2H-1-Benzopyran-8-carboxylic acid, 3-[bis(phenylmethyl)amino]-3,4-dihydro-
5-(4-methyl-1-piperazinyl)-, methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 9 OF 22 USPATFULL on STN

AB Disclosed are compounds of the formula: ##STR1##

or the pharmaceutically acceptable acid addition salts thereof wherein:

R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are the same or different and represent hydrogen, halogen, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.4 alkylthio, hydroxy, amino, mono- or di(C.sub.1-C.sub.6)alkylamino, cyano, nitro, trifluoromethyl or trifluoromethoxy; and

10/714,577

10/27/04


X is oxygen, a bond, C.sub.1-C.sub.2 alkylene, or methyleneoxy, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:100376 USPATFULL
TI 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands
IN Tran, Jennifer N., Branford, CT, United States
Thurkauf, Andrew, Danbury, CT, United States
PA Neurogen Corporation (01)
PI US 2001005753 A1 20010628
US 6333329 B2 20011225
AI US 2001-761048 A1 20010116 (9)
RLI Continuation of Ser. No. US 1999-343309, filed on 30 Jun 1999, PENDING
PRAI US 1998-91250P 19980630 (60) <--
DT Utility
FS APPLICATION
LREP Steven J. Sarussi, McDonnell Boehnen Hulbert & Berghoff, 32nd Floor, 300 S. Wacker Drive, Chicago, IL, 60606
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 670

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 253689-50-8P, 1-(Chroman-6-yl)-4-(4-methylbenzyl)piperazine (preparation of (arylalkylpiperazinyl)benzodioxane and (arylalkylpiperazinyl)chroman derivs. as subtype-specific dopamine receptor ligands)
RN 253689-50-8 USPATFULL
CN Piperazine, 1-(3,4-dihydro-2H-1-benzopyran-6-yl)-4-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 10 OF 22 USPATFULL on STN
AB Disclosed are compounds of the formula: ##STR1##

or the pharmaceutically acceptable acid addition salts thereof wherein:

R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are the same or different and represent hydrogen, halogen, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.4 alkylthio, hydroxy, amino, mono- or di(C.sub.1 -C.sub.6)alkylamino, cyano, nitro, trifluoromethyl or trifluoromethoxy; and

X is oxygen, a bond, C.sub.1 -C.sub.2 alkylene, or methyleneoxy, which compounds are useful for the treatment and/or prevention of

10/714,577

10/27/04


neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:11028 USPATFULL
TI 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands
IN Tran, Jennifer N., Guilford, CT, United States
Thurkauf, Andrew, Danbury, CT, United States
PA Neurogen Corporation, Branford, CT, United States (U.S. corporation)
PI US 6177566 B1 20010123
AI US 1999-343309 19990630 (9)
PRAI US 1998-91250P 19980630 (60) <--
DT Utility
FS Granted
EXNAM Primary Examiner: Bernhardt, Emily
LREP McDonnell Boehnen Hulbert & Berghoff
CLMN Number of Claims: 29
ECL Exemplary Claim: 1,11,16,17
DRWN No Drawings
LN.CNT 690

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 253689-50-8P, 1-(Chroman-6-yl)-4-(4-methylbenzyl)piperazine
(preparation of (arylalkylpiperazinyl)benzodioxane and
(arylalkylpiperazinyl)chroman derivs. as subtype-specific dopamine
receptor ligands)
RN 253689-50-8 USPATFULL
CN Piperazine, 1-(3,4-dihydro-2H-1-benzopyran-6-yl)-4-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 11 OF 22 USPATFULL on STN

AB The invention relates to a combination of a first component (a) which is a selective 5-HT_{1A} receptor antagonist having the formula I wherein R_{sub.1} is n-propyl or cyclobutyl, R_{sub.2} is isopropyl, tertiary butyl, cyclobutyl, cyclopentyl or cyclohexyl, R_{sub.3} is hydrogen and R_{sub.4} is hydrogen or methyl and being in the (R)-enantiomer form, with a second component (b) which is a selective h5-HT_{1B} antagonist or partial agonist having the formula II ##STR1## wherein X is CH_{sub.2}, O, Y is CONH, NHCO, R_{sub.1} is H, C_{sub.1}-C_{sub.6} alky, C_{sub.3}-C_{sub.6} cycloalkyl, R_{sub.2} is H, C_{sub.1}-C_{sub.6} alkyl, C_{sub.1}-C_{sub.6} alkoxy, halogen,

R_{sub.3} is ##STR2## R_{sub.4} and R_{sub.5} independently are H or C_{sub.1}-C_{sub.4} alkyl as racemate, R-enantiomer or S-enantiomer, and said components (a) and (b) being in the form of free bases, solvates or pharmaceutically acceptable salts thereof, the preparation thereof, pharmaceutical formulations containing said combination, use of and method of treatment of affective disorders such as depression, anxiety

10/714,577

10/27/04

and OCD with said combination as well as a kit containing said combination.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:168019 USPATFULL
TI Combination of a selective 5-HT.sub.1A antagonist and a selective
ub. h5-HT.sub.1B antagonist or partial agonist
IN Berg, Stefan, Ekero, Sweden
Ross, Svante, Sodertalje, Sweden
Thorberg, Seth-Olov, Strangnas, Sweden
PA AstraZeneca AB, Sodertalje, Sweden (non-U.S. corporation)
PI US 6159972 20001212
WO 9913876 19990325
AI US 1998-171581 19981021 (9)
WO 1998-SE1600 19980909
19981021 PCT 371 date
19981021 PCT 102(e) date
PRAI SE 1997-3374 19970918 <--
DT Utility
FS Granted
EXNAM Primary Examiner: Jarvis, William R. A.
LREP White & Case LLP
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 2058

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 221472-06-6P

(byproduct; preparation and/or therapeutic combination of selective 5-HT1A
antagonists with selective h5-HT1B antagonists or partial agonists)

RN 221472-06-6 USPATFULL

CN 2H-1-Benzopyran-3-amine, 3,4-dihydro-8-methyl-5-(4-methyl-1-piperazinyl)-
N,N-bis(phenylmethyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 12 OF 22 USPATFULL on STN

AB The invention relates to a combination of a first component (a) which is
a 5-HT reuptake inhibitor and a second component (b) which is selective
h5-HT.sub.1B antagonist or partial agonist having the formula I ##STR1##
wherein X is CH.sub.2, O; Y is CONH, NHCO;

10/714,577

10/27/04

R.sub.1 is H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl;

R.sub.2 is H, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, halogen;

R.sub.3 is ##STR2## R.sub.4 and R.sub.5 independently are H or C.sub.1 -C.sub.4 alkyl, as racemate, R-enantiomer or S-enantiomer, and said components (a) and (b) being in the form of free bases, solvents or pharmaceutically acceptable salts thereof, the preparation thereof, pharmaceutical formulations containing said combination, use of and method of treatment of affective disorders such as depression, anxiety and OCD with said combination as well as a kit containing said combination.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:168018 USPATFULL
TI Combination of a 5-HT reuptake inhibitor and a H5-HT1B anatagonist or partial agonist
IN Berg, Stefan, Ekero, Sweden
Ross, Svante, Sodertalje, Sweden
Thorberg, Seth-Olov, Strangnas, Sweden
PA Astrazeneca AB, Sodertalje, Sweden (non-U.S. corporation)
PI US 6159971 20001212
WO 9913877 19990325
AI US 1998-171580 19981021 (9)
WO 1998-SE1601 19980909
19981021 PCT 371 date
19981021 PCT 102(e) date
PRAI SE 1997-3375 19970918 <--
DT Utility
FS Granted
EXNAM Primary Examiner: Jarvis, William R. A.
LREP White & Case LLP
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1984

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 221472-06-6P

(byproduct; preparation and/or therapeutic combination of 5-HT reuptake inhibitors with selective h5-HT1B antagonists or partial agonists)


RN 221472-06-6 USPATFULL

CN 2H-1-Benzopyran-3-amine, 3,4-dihydro-8-methyl-5-(4-methyl-1-piperazinyl)-N,N-bis(phenylmethyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/714,577

10/27/04



L8 ANSWER 13 OF 22 USPATFULL on STN

AB The invention relates to a combination of a first component (a) which is a monoamine oxidase inhibitor and a second component (b) which is selective h5-HT.sub.1B antagonist or partial agonist having the formula I ##STR1## wherein X is CH.sub.2, O; Y is CONH, NHCO;

R.sub.1 is H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl;

R.sub.2 is H, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, halogen;

R.sub.3 is ##STR2## R.sub.4 and R.sub.5 independently are H or C.sub.1 -C.sub.4 alkyl, as racemate, R-enantiomer or S-enantiomer, and said components (a) and (b) being in the form of free bases, solvates or pharmaceutically acceptable salts thereof, the preparation thereof, pharmaceutical formulations containing said combination, use of and method of treatment of affective disorders such as depression, anxiety and OCD with said combination as well as a kit containing said combination.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:168017 USPATFULL

TI Combination of a monoamine oxidase inhibitor and a h5-HT.sub.1B antagonist or partial agonist

IN Berg, Stefan, Ekero, Sweden

Ross, Svante, Sodertalje, Sweden

Thorberg, Seth-Olov, Strangnas, Sweden

PA Astrazeneca AB, Sodertalje, Sweden (non-U.S. corporation)

PI US 6159970 20001212

WO 9913878 19990325

AI US 1998-171578 19981021 (9)

WO 1998-SE1602 19980909

19981021 PCT 371 date

19981021 PCT 102(e) date

PRAI SE 1997-3376 19970918 <--

DT Utility

FS Granted

EXNAM Primary Examiner: Jarvis, William R. A.

LREP White & Case LLP

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

10/714,577

10/27/04

LN.CNT 1971

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 221472-06-6P

(byproduct; preparation and/or therapeutic combination of selective 5-HT1A antagonists with selective h5-HT1B antagonists or partial agonists)

RN 221472-06-6 USPATFULL

CN 2H-1-Benzopyran-3-amine, 3,4-dihydro-8-methyl-5-(4-methyl-1-piperazinyl)-N,N-bis(phenylmethyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 14 OF 22 USPATFULL on STN

AB Piperidine and piperazine derivatives of the formula I ##STR1## wherein Ind is an indol-3-yl radical which is unsubstituted or mono- or polysubstituted by OH, OA, CN, Hal, COR.sup.2 or CH.sub.2 R.sup.2,

R.sup.1 is benzofuran-5-yl or 2,3-dihydrobenzofuran-5-yl, chroman-6-yl, chroman-4-on-6-yl, 3-chromen-6-yl or chromen-4-on-6-yl, which is unsubstituted or monosubstituted by CN, CH.sub.2 OH, CH.sub.2 OA or COR.sup.2,

Q is C.sub.m H.sub.2m,

N or CR.sup.3,

A is alkyl having 1-6 C atoms,

Hal is F, Cl, Br or I,

R.sup.2 is OH, OA, NH.sub.2, NHA or NA.sub.2,

R.sup.3 is H, OH or OA and

m is 2, 3 or 4,

and their physiologically acceptable salts, are active on the central nervous system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AN 96:58215 USPATFULL

TI Piperidines and piperazines

10/714,577

10/27/04

IN Bottcher, Henning, Darmstadt, Germany, Federal Republic of
Seyfried, Christoph, Seeheim-Jugenheim, Germany, Federal Republic of
Bartoszyk, Gerd, Darmstadt, Germany, Federal Republic of
Greiner, Hartmut, Darmstadt, Germany, Federal Republic of
PA Merck Patent Gesellschaft mit beschränkter Haftung, Darmstadt, Germany,
Federal Republic of (non-U.S. corporation)
PI US 5532241 19960702
AI US 1994-314734 19940929 (8)
PRAI DE 1993-4333254 19930930 <--
DT Utility
FS Granted
EXNAM Primary Examiner: Bernhardt, Emily
LREP Millen, White, Zelano & Branigan
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 936
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 163521-05-9P
(preparation of (indolylalkyl)piperidines and -piperazines as drugs)
RN 163521-05-9 USPATFULL
CN 1H-Indole, 3-[4-[4-(3,4-dihydro-2H-1-benzopyran-6-yl)-1-piperazinyl]butyl]-
5-methoxy- (9CI) (CA INDEX NAME)



L8 ANSWER 15 OF 22 USPATFULL on STN
AB A method for detecting hydrogen peroxide wherein a sample is contacted
with a peroxidase or a peroxidatively-active substance and a redox
indicator of the following ##STR1## in which A and D independently of
one another represent phenyl, pyridyl or imidazolyl,

G represents O, CH.sub.2 or S,

m represents the number zero or one, and

X represents O, ##STR2## or --NR.sup.1 --NR.sup.2 -- R.sup.1 and
R.sup.2, independently of one another, denote hydrogen, alkyl,
cycloalkyl, aryl or aralkyl, or --NR.sup.1 R.sup.2 together represent a
pyrrolidine, pyrazoline, piperidine, piperazine or morpholine radical
and

T denotes hydrogen, hydroxyl, alkyl, aryl, alkoxy, phenoxy, SO.sub.3 H,
--COOH or ##STR3## whereby a color change is brought out if hydrogen
peroxide is present.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 91:8714 USPATFULL
TI Method for detecting hydrogen peroxide employing triaryl- and
trihetarylmethane derivatives as redox indicators
IN Heidenreich, Holger, Cologne, Germany, Federal Republic of

10/714,577

10/27/04

Wolfrum, Gerhard, Leverkusen, Germany, Federal Republic of
Wehling, Klaus, Wuppertal, Germany, Federal Republic of
Hugl, Herbert, Bergisch Gladbach, Germany, Federal Republic of
PA Bayer Aktiengesellschaft, Leverkusen, Germany, Federal Republic of
(non-U.S. corporation)
PI US 4988616 19910129
AI US 1989-302072 19890124 (7)
RLI Continuation of Ser. No. US 1987-53301, filed on 22 May 1987, now
abandoned
PRAI DE 1986-3619436 19860610 <--
DT Utility
FS Granted
EXNAM Primary Examiner: Hill, Jr., Robert J.
LREP Sprung Horn Kramer & Woods
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 476
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 114608-33-2P
(preparation of, as redox indicators)
RN 114608-33-2 USPATFULL
CN Spiro[1H-isoindole-1,9'-[9H]xanthen]-3(2H)-one, 2-amino-3',6'-bis(4-methyl-
1-piperazinyl)- (9CI) (CA INDEX NAME)




L8 ANSWER 16 OF 22 USPATFULL on STN
AB Blood-pressure lowering compounds having a structure as shown in the
accompanying formula sheets.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 89:41190 USPATFULL
TI Blood-pressure lowering 4-bicyclic-1-piperazinyl-alkyl amides
IN Hartog, Jan, Weesp, Netherlands
Wouters, Wouter, Weesp, Netherlands
van Wijngaarden, Lneke, Weesp, Netherlands
PA Duphar International Research B.V., Weesp, Netherlands (non-U.S.
corporation)
PI US 4833142 19890523
AI US 1987-118005 19871109 (7)
RLI Continuation-in-part of Ser. No. US 1984-660054, filed on 12 Oct 1984,
now abandoned which is a continuation-in-part of Ser. No. US
1985-805809, filed on 12 Jun 1985, now abandoned
PRAI NL 1983-3569 19831017 <--
DT Utility
FS Granted
EXNAM Primary Examiner: Hollrah, Glennon H.; Assistant Examiner: Turnipseed,

10/714,577


10/27/04

James H.
LREP Stevens, Davis, Miller & Mosher
CLMN Number of Claims: 12
ECL Exemplary Claim: 1,12
DRWN 39 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 739
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 98224-08-9P
(preparation of)
RN 98224-08-9 USPATFULL
CN Benzamide, N-[2-[4-(3,4-dihydro-2H-1-benzopyran-8-yl)-1-piperazinyl]ethyl]-
4-fluoro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L8 ANSWER 17 OF 22 USPATFULL on STN
AB An excellent pressure sensitive copying paper is provided by applying as a color former certain encapsulated 6-di lower alkyl amino-naphthalfluoran compounds to either a single sheet or to the upper leaf of a pressure sensitive paper. The color former is soluble in aromatic solvents and also has excellent light fastness.

10/714,577

10/27/04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AN 76:67817 USPATFULL
TI Pressure sensitive copying paper
IN Seki, Hiromitsu, Osaka, Japan
Yamamoto, Kenji, Osaka, Japan
PA Yamamoto Kagaku Gosei Kabushiki Kaisha, Japan (non-U.S. corporation)
PI US 3997561 19761214
AI US 1971-208415 19711215 (5)
PRAI JP 1970-112053 19701215 <--
DT Utility
FS Granted
EXNAM Primary Examiner: Milestone, Norma S.
LREP Armstrong, Nikaido & Wegner
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 238

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 52546-96-0P

(preparation of)

RN 52546-96-0 USPATFULL
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-(diethylamino)-2'-[4-(4-methoxyphenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 18 OF 22 USPATFULL on STN

AB An excellent pressure sensitive copying paper is provided by applying a color former certain encapsuled 6-di lower alkyl amino-naphthalfluoran compounds to either a single sheet or to the upper leaf of a pressure sensitive paper. The color former is soluble in aromatic solvents and also has excellent light fastness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 75:5886 USPATFULL
TI PRESSURE SENSITIVE COPYING PAPER
IN Seki, Hiromitsu, Osaka, Japan
Yamamoto, Kenji, Osaka, Japan
PA Yamamoto Kagaku Gosei Kabushiki Kaisha, Osaka, Japan (non-U.S. corporation)
PI US 3864145 19750204
AI US 1972-310585 19721129 (5)
RLI Division of Ser. No. US 1971-208415, filed on 15 Dec 1971, now Defensive Publication No.
PRAI JP 1970-112053 19701215 <--
DT Utility
FS Granted

10/714,577

10/27/04

EXNAM Primary Examiner: Herbert, Jr., Thomas J.

LREP Armstrong, Nikaido & Wegner

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 255


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 52546-96-0P

(preparation of)

RN 52546-96-0 USPATFULL

CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-(diethylamino)-2'-[4-(4-methoxyphenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 19 OF 22 USPAT2 on STN

AB The present invention relates to new new piperidyl- or piperazinyl-substituted dihydro-2H-1-benzopyran derivatives compound having the formula (I) ##STR1##

wherein

X is N or CH;

Y is NR.sub.2CH.sub.2, CH.sub.2NR.sub.2, NR.sub.2CO, CONR.sub.2, NR.sub.2SO.sub.2 or NR.sub.2CONR.sub.2

wherein R.sub.2 is H or C.sub.1-C.sub.6 alkyl;

R.sub.1 is H, C.sub.1-C.sub.6 alkyl or C.sub.3-C.sub.6 cycloalkyl;

R.sub.3 is C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.6 cycloalkyl or (CH.sub.2).sub.n-aryl,

wherein aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted with R.sub.4 and/or R.sub.5;

and n is 0-4;

as (R)-enantiomers, (S)-enantiomers or a racemate in the form of a free base or a pharmaceutically acceptable salt or solvate thereof, a process for their preparation, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:146809 USPAT2

10/714,577


10/27/04

TI Substituted chroman derivatives
IN Berg, Stefan, Ekero, SWEDEN
Nylof, Martin, Sodertalje, SWEDEN
Ross, Svante, Sodertalje, SWEDEN
Thorberg, Seth-Olov, Strangnas, SWEDEN
PA AstraZeneca AB, Sodertalje, SWEDEN (non-U.S. corporation)
PI US 6670359 B2 20031230
AI US 2002-285743 20021101 (10)
RLI Division of Ser. No. US 171570, now patented, Pat. No. US 6479497
PRAI SE 1997-3377 19970918 <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Desai, Rita
LREP White & Case LLP
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1918
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 221185-02-0P

(preparation of substituted chroman derivs. and their effects at the h5-HT1B receptor)

RN 221185-02-0 USPAT2
CN 2,6-Piperazinedione, 1-[(3S)-3-[bis(phenylmethyl)amino]-3,4-dihydro-2H-1-benzopyran-5-yl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L8 ANSWER 20 OF 22 USPAT2 on STN
AB The present invention relates to indole and 2,3-dihydroindole derivatives having formula (I) ##STR1##

or any of its any of its enantiometers or any mixture thereof, or an acid addition salt thereof, wherein A, R.sup.1, R.sup.2, R.sup.3, W, X, Y and Z are as described in the description. The compounds are potent serotonin reuptake inhibitors and have 5-HT.sub.1A receptor antagonistic activity.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:24207 USPAT2
TI Indole and 2,3-dihydroindole derivatives, their preparation and use
IN Moltzen, Ejner Knud, Gentofte, DENMARK
Perregaard, Jens Kristian, Jaegerspris, DENMARK

10/714,577

10/27/04

Mikkelsen, Ivan, Koge, DENMARK
Smith, Garrick Paul, Valby, DENMARK
PA H. Lundbeck A/S, Copenhagen-Valby, DENMARK (non-U.S. corporation)
PI US 6727263 B2 20040427
AI US 2002-223046 20020816 (10)
RLI Division of Ser. No. US 2000-491204, filed on 25 Jan 2000, now patented,
Pat. No. US 6476035 Continuation of Ser. No. WO 1998-DK336, filed on 20
Jul 1998
PRAI DK 1997-892 19970725 <--
US 1997-53713P 19970725 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Bernhardt, Emily
LREP Datby & Darby
CLMN Number of Claims: 26
ECL Exemplary Claim: 1,13
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1281
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 220251-33-2P
(preparation of indole and 2,3-dihydroindole derivs. as potent serotonin
reuptake inhibitors and 5-HT1A receptor antagonists)
RN 220251-33-2 USPAT2
CN 1H-Indole, 6-chloro-3-[2-[4-(6-chloro-3,4-dihydro-2,2-dimethyl-2H-1-
benzopyran-8-yl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 21 OF 22 USPAT2 on STN
AB Disclosed are compounds of the formula: ##STR1##

or the pharmaceutically acceptable acid addition salts thereof wherein:

R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are the same or different and represent hydrogen, halogen, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.4 alkylthio, hydroxy, amino, mono- or di(C.sub.1-C.sub.6)alkylamino, cyano, nitro, trifluoromethyl or trifluoromethoxy; and

X is oxygen, a bond, C.sub.1-C.sub.2 alkylene, or methyleneoxy,


which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:186135 USPAT2

10/714,577

10/27/04

TI 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands
IN Tran, Jennifer N., Guilford, CT, United States
Thurkauf, Andrew, Danbury, CT, United States
PA Neurogen Corporation, Brandford, CT, United States (U.S. corporation)
PI US 6486164 B2 20021126
AI US 2001-27150 20011220 (10)
RLI Continuation of Ser. No. US 2001-761048, filed on 16 Jan 2001, now patented, Pat. No. US 6333329 Continuation of Ser. No. US 1999-343309, filed on 30 Jun 1999, now patented, Pat. No. US 6177566
PRAI US 1998-91250P 19980630 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Bernhardt, Emily
LREP McDonnell Boehnen Hulbert & Berghoff
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 633
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 253689-50-8P, 1-(Chroman-6-yl)-4-(4-methylbenzyl)piperazine
(preparation of (arylalkylpiperazinyl)benzodioxane and
(arylalkylpiperazinyl)chroman derivs. as subtype-specific dopamine
receptor ligands)
RN 253689-50-8 USPAT2
CN Piperazine, 1-(3,4-dihydro-2H-1-benzopyran-6-yl)-4-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 22 OF 22 USPAT2 on STN
AB Disclosed are compounds of the formula: ##STR1##

or the pharmaceutically acceptable acid addition salts thereof wherein:

R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are the same or different and represent hydrogen, halogen, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.4 alkylthio, hydroxy, amino, mono- or di(C.sub.1 -C.sub.6)alkylamino, cyano, nitro, trifluoromethyl or trifluoromethoxy; and

X is oxygen, a bond, C.sub.1 -C.sub.2 alkylene, or methyleneoxy, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:100376 USPAT2
TI 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands

10/714,577

10/27/04

IN Tran, Jennifer N., Guilford, CT, United States
Thurkauf, Andrew, Danbury, CT, United States
PA Neurogen Corporation, Branford, CT, United States (U.S. corporation)
PI US 6333329 B2 20011225
AI US 2001-761048 20010116 (9)
RLI Continuation of Ser. No. US 1999-343309, filed on 30 Jun 1999, now
patented, Pat. No. US 6177566
PRAI US 1998-91250P 19980630 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Bernhardt, Emily
LREP McDonnell Boehnen Hulbert & Berghoff, Sarussi, Steven J.
CLMN Number of Claims: 29
ECL Exemplary Claim: 1,11
DRWN No Drawings
LN.CNT 693
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **253689-50-8P**, 1-(Chroman-6-yl)-4-(4-methylbenzyl)piperazine
(preparation of (arylalkylpiperazinyl)benzodioxane and
(arylalkylpiperazinyl)chroman derivs. as subtype-specific dopamine
receptor ligands)
RN 253689-50-8 USPAT2
CN Piperazine, 1-(3,4-dihydro-2H-1-benzopyran-6-yl)-4-[(4-
methylphenyl)methyl]- (9CI) (CA INDEX NAME)




=>

10/714,577


10/27/04

=> d abs bib fhitr 1-5

L9 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I



II

AB The invention relates to a combination of a first component (a) which is a monoamine oxidase inhibitor (MAOI) and a second component (b) which is a selective h5-HT1B antagonist or partial agonist I [wherein X = CH2 or O; Y = CONH or NHCO; R1 = H, C1-6 alkyl, or C3-6 cycloalkyl; R2 = H, C1-6 alkyl, C1-6 alkoxy, or halo; R3 = morpholino, morpholinocarbonyl, 4-oxopiperidino, CF3, or CONR4R5; R4, R5 = H or C1-4 alkyl], as a racemate or either enantiomer, with said components (a) and (b) being in the form of free bases, solvates, or pharmaceutically acceptable salts. The invention also relates to their preparation, combination pharmaceutical formulations, use, a method of treating affective disorders such as depression, anxiety, and OCD using the combinations, as well as a kit containing the combinations. The combinations of the invention may afford a new route to faster onset of action in antidepressant therapy, and may also improve the efficacy of MAOIs. For instance, amidation of 4-morpholinobenzoic acid with (R)-2-amino-5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalene using 1,1'-carbonyldiimidazole in DMF gave 73% II. Using II as the h5-HT1B antagonist, and phenelzine as the MAOI, an almost 400% maximum increase in extracellular 5-HT was observed in the prefrontal cortex of guinea pigs, whereas phenelzine alone gave a maximum increase of approx. 225%.

AN 1999:219987 CAPLUS

DN 130:252383

TI A combination of a monoamine oxidase inhibitor and a h5-HT1B antagonist or partial agonist [piperazinonaphthalene or -benzopyran derivative] for antidepressant therapy

IN Berg, Stefan; Ross, Svante; Thorberg, Seth-Olov

PA Astra Aktiebolag, Swed.

SO PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DT Patent

10/714,577


10/27/04

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9913878	A1	19990325	WO 1998-SE1602	19980909
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9807804	A	19990318	ZA 1998-7804	19980827
	CA 2302204	AA	19990325	CA 1998-2302204	19980909
	AU 9891931	A1	19990405	AU 1998-91931	19980909
	AU 752719	B2	20020926		
	EP 1014986	A1	20000705	EP 1998-944376	19980909
	EP 1014986	B1	20040714		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9812236	A	20000718	BR 1998-12236	19980909
	TR 200000725	T2	20000821	TR 2000-200000725	19980909
	EE 200000146	A	20010215	EE 2000-200000146	19980909
	JP 2001516719	T2	20011002	JP 2000-511500	19980909
	AT 270889	E	20040715	AT 1998-944376	19980909
	US 6159970	A	20001212	US 1998-171578	19981021
	NO 2000001400	A	20000505	NO 2000-1400	20000317
PRAI	SE 1997-3376	A	19970918		
	WO 1998-SE1602	W	19980909		
OS	MARPAT 130:252383				
IT	221185-15-5P, (S)-3-Amino-8-methyl-5-(4-methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(intermediate; preparation and/or therapeutic combination of selective 5-HT1A antagonists with selective h5-HT1B antagonists or partial agonists)				
RN	221185-15-5 CAPLUS				
CN	2H-1-Benzopyran-3-amine, 3,4-dihydro-8-methyl-5-(4-methyl-1-piperazinyl)-, (3S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.




10/714,577

10/27/04

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
GI



AB The invention relates to a combination of a first component (a) which is a 5-HT reuptake inhibitor (SSRI), and a second component (b) which is a selective h5-HT1B antagonist or partial agonist I [wherein X = CH2 or O; Y = CONH or NHCO; R1 = H, C1-6 alkyl, or C3-6 cycloalkyl; R2 = H, C1-6 alkyl, C1-6 alkoxy, or halo; R3 = morpholino, morpholinocarbonyl, 4-oxopiperidino, CF3, or CONR4R5; R4, R5 = H or C1-4 alkyl], as a racemate or either enantiomer, with said components (a) and (b) being in the form of free bases, solvates, or pharmaceutically acceptable salts. The invention also relates to their preparation, combination pharmaceutical formulations, use, a method of treating affective disorders such as depression, anxiety, and OCD using the combinations, as well as a kit containing the combinations. The combinations of the invention may afford a new route to faster onset of action in antidepressant therapy, and may improve the efficacy of SSRIs. For instance, amidation of 4-morpholinobenzoic acid with (R)-2-amino-5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalene using 1,1'-carbonyldiimidazole in DMF gave 73% II. Using II as the h5-HT1B antagonist, and citalopram as the 5-HT reuptake inhibitor, a 400% maximum increase in extracellular 5-HT was observed in the prefrontal cortex of guinea pigs, whereas citalopram alone gave a maximum increase of less than 250%.

AN 1999:219986 CAPLUS

DN 130:252382

TI A combination of a 5-HT reuptake inhibitor and a h5-HT1B antagonist or partial agonist [piperazinonaphthalene or -benzopyran derivative] for antidepressant therapy

IN Berg, Stefan; Ross, Svante; Thorberg, Seth-Olov

PA Astra Aktiebolag, Swed.

SO PCT Int. Appl., 76 pp.

10/714,577

10/27/04

CODEN: PIXXD2


DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9913877	A1	19990325	WO 1998-SE1601	19980909
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9807817	A	19990318	ZA 1998-7817	19980827
	CA 2302382	AA	19990325	CA 1998-2302382	19980909
	AU 9891930	A1	19990405	AU 1998-91930	19980909
	AU 752722	B2	20020926		
	EP 1014985	A1	20000705	EP 1998-944375	19980909
	EP 1014985	B1	20030521		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200000727	T2	20000921	TR 2000-200000727	19980909
	BR 9812088	A	20000926	BR 1998-12088	19980909
	EE 200000141	A	20010215	EE 2000-200000141	19980909
	EE 4141	B1	20031015		
	JP 2001516718	T2	20011002	JP 2000-511499	19980909
	NZ 503171	A	20020201	NZ 1998-503171	19980909
	AT 240733	E	20030615	AT 1998-944375	19980909
	RU 2214824	C2	20031027	RU 2000-109563	19980909
	PT 1014985	T	20031031	PT 1998-944375	19980909
	ES 2200370	T3	20040301	ES 1998-944375	19980909
	US 6159971	A	20001212	US 1998-171580	19981021
	NO 2000001399	A	20000510	NO 2000-1399	20000317
	HK 1032739	A1	20031031	HK 2000-107438	20001121
PRAI	SE 1997-3375	A	19970918		
	WO 1998-SE1601	W	19980909		
OS	MARPAT 130:252382				
IT	221185-15-5P, (S)-3-Amino-8-methyl-5-(4-methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(intermediate; preparation and/or therapeutic combination of 5-HT reuptake inhibitors with selective h5-HT1B antagonists or partial agonists)				
RN	221185-15-5 CAPLUS				
CN	2H-1-Benzopyran-3-amine, 3,4-dihydro-8-methyl-5-(4-methyl-1-piperazinyl)-, (3S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

10/714,577

10/27/04



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a combination of a first component (a) which is a selective 5-HT_{1A} receptor antagonist I [wherein R₁ = Pr or cyclobutyl, R₂ = iso-Pr, tert-Bu, cyclobutyl, cyclopentyl, or cyclohexyl; R₃ = H and R₄ = H or Me], being in the (R)-enantiomer form, with a second component (b) which is a selective h₅-HT_{1B} antagonist or partial agonist II [wherein X = CH₂ or O; Y = CONH or NHCO; R₁ = H, C₁-6 alkyl, or C₃-6 cycloalkyl; R₂ = H, C₁-6 alkyl, C₁-6 alkoxy, or halo; R₃ = morpholino, morpholinocarbonyl, 4-oxopiperidino, CF₃, or CONR₄R₅; R₄, R₅ = H or C₁-4 alkyl], as a racemate or either enantiomer, with said components (a) and (b) being in the form of free bases, solvates, or pharmaceutically acceptable salts. The invention also relates to their preparation, combination pharmaceutical formulations, use, a method of treating affective disorders such as depression, anxiety, and OCD using the combinations, as well as a kit containing the combinations. The combinations of the invention may afford a new route to faster onset of action in antidepressant therapy. For instance, amidation of 4-morpholinobenzoic acid with (R)-2-amino-5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalene using 1,1'-carbonyldiimidazole in DMF gave 73% III. Using III as the h₅-HT_{1B} antagonist, and benzopyrancarboxamide derivative IV (tartrate salt) as the 5-HT_{1A} antagonist, a synergistic increase in 5-HT turnover was obtained in 4 brain regions of guinea pigs, as compared with compound III alone.

AN 1999:219985 CAPLUS

DN 130:252381

TI A combination of a selective 5-HT_{1A} antagonist [benzopyran derivative] and a selective h₅-HT_{1B} antagonist or partial agonist [piperazinonaphthalene or -benzopyran derivative] for antidepressant therapy

IN Berg, Stefan; Ross, Svante; Thorberg, Seth-Olov

PA Astra Aktiebolag, Swed.

SO PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DT Patent

10/714,577

10/27/04

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9913876	A1	19990325	WO 1998-SE1600	19980909
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9807810	A	19990218	ZA 1998-7810	19980827
	TW 568786	B	20040101	TW 1998-87114345	19980829
	CA 2302383	AA	19990325	CA 1998-2302383	19980909
	AU 9891929	A1	19990405	AU 1998-91929	19980909
	AU 752718	B2	20020926		
	BR 9812234	A	20000718	BR 1998-12234	19980909
	EP 1021183	A1	20000726	EP 1998-944374	19980909
	EP 1021183	B1	20040317		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200000734	T2	20001121	TR 2000-200000734	19980909
	EE 200000143	A	20010215	EE 2000-200000143	19980909
	EE 4142	B1	20031015		
	JP 2001516717	T2	20011002	JP 2000-511498	19980909
	NZ 503174	A	20020301	NZ 1998-503174	19980909
	RU 2215528	C2	20031110	RU 2000-109558	19980909
	AT 261728	E	20040415	AT 1998-944374	19980909
	PT 1021183	T	20040730	PT 1998-944374	19980909
	US 6159972	A	20001212	US 1998-171581	19981021
	NO 2000001398	A	20000404	NO 2000-1398	20000317
PRAI	SE 1997-3374	A	19970918		
	WO 1998-SE1600	W	19980909		
OS	MARPAT 130:252381				
IT	221185-15-5P, (S)-3-Amino-8-methyl-5-(4-methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(intermediate; preparation and/or therapeutic combination of selective 5-HT1A antagonists with selective h5-HT1B antagonists or partial agonists)				
RN	221185-15-5 CAPLUS				
CN	2H-1-Benzopyran-3-amine, 3,4-dihydro-8-methyl-5-(4-methyl-1-piperazinyl)-, (3S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


10/714,577

10/27/04



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
GI



I

AB Title compds. [I; X is N or CH; Y is NR₂CH₂, CH₂NR₂, NR₂CO, CONR₂, NR₂SO₂; R₂ is H or C₁-C₆ alkyl; R₁ is H, C₁-C₆ alkyl or C₃-C₆ cycloalkyl; R₃ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, (CH₂)_n-aryl; aryl is Ph or a heteroarom. ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted; n is 0-4; R₉ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, OCF₃, OCHF₂, OCH₂F, halogen, CONR₆R₇, CN, CF₃, OH, C₁-C₆ alkoxy, NR₆R₇, SO₃CH₃, SO₃CF₃, SO₂NR₆R₇, an unsubstituted or substituted heterocyclic or heteroarom. ring containing one or two heteroatoms selected from N and O, wherein the substituent(s) is(are) C₁-C₆ alkyl, COR₈; R₆, R₇ and R₈ are as defined above], as (R)-enantiomers, (S)-enantiomers or racemates in the form of a free base or pharmaceutically acceptable salts or solvates thereof are prepared via acylation and alkylation; pharmaceutical compns. containing said therapeutically active compds. and to the use of said active compds. in therapy are included. (S)-N-[8-methyl-5-(4-methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran-3-yl]-4-(dimethylaminocarbonyl)benzamide was prepared

AN 1999:216915 CAPLUS

DN 130:223067

TI Preparation of substituted chroman derivatives

10/714,577

10/27/04


IN Berg, Stefan; Linderberg, Mats; Ross, Svante; Thorberg, Seth-Olov; Ulff,
Bengt
PA Astra Aktiebolag, Swed.
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9914213	A1	19990325	WO 1998-SE1604	19980909
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9807806	A	19990318	ZA 1998-7806	19980827
	CA 2303926	AA	19990325	CA 1998-2303926	19980909
	AU 9891933	A1	19990405	AU 1998-91933	19980909
	BR 9812239	A	20000718	BR 1998-12239	19980909
	EP 1025096	A1	20000809	EP 1998-944378	19980909
	EP 1025096	B1	20031126		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200000737	T2	20000921	TR 2000-200000737	19980909
	EE 200000144	A	20010215	EE 2000-200000144	19980909
	JP 2001516755	T2	20011002	JP 2000-511762	19980909
	AT 255099	E	20031215	AT 1998-944378	19980909
	US 6387899	B1	20020514	US 1998-171572	19981021
	HR 2000000133	A1	20011231	HR 2000-133	20000309
	NO 2000001403	A	20000518	NO 2000-1403	20000317
	US 6384225	B1	20020507	US 2000-653552	20000831
PRAI	SE 1997-3378	A	19970918		
	WO 1998-SE1604	W	19980909		
	US 1998-171572	A3	19981021		
OS	MARPAT 130:223067				
IT	221185-15-5P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of substituted chroman derivs.)				
RN	221185-15-5 CAPLUS				
CN	2H-1-Benzopyran-3-amine, 3,4-dihydro-8-methyl-5-(4-methyl-1-piperazinyl)-, (3S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


10/714,577

10/27/04



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
GI



AB Piperidyl- or piperazinyl-substituted dihydro-2H-1-benzopyran derivs. I [X = N, CH; Y = NR₂CH₂, CH₂NR₂, NR₂CO, CONR₂, NR₂SO₂, NR₂CONR₂ wherein R₂ = H, C₁-C₆ alkyl; R₁ = H, C₁-C₆ alkyl, C₃-C₆ cycloalkyl; R₃ = C₁-C₆ alkyl, C₃-C₆ cycloalkyl, (CH₂)_n-aryl, wherein aryl is Ph or a heteroarom. ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted; n = 0-4], possessing selective effects at the h₅-HT_{1B} receptor, were prepared E.g., reaction of (S)-N-[5-(4-methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran-3-yl]-4-(piperazin-1-yl)benzamide with 2-benzyloxyethyl mesylate in presence of K₂CO₃ gave (S)-N-[5-(4-methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran-3-yl]-4-[4-(2-benzyloxyethyl)piperazin-1-yl]benzamide.

AN 1999:216914 CAPLUS

DN 130:237475

TI Preparation of substituted chroman derivatives and their effects at the h₅-HT_{1B} receptor

IN Berg, Stefan; Nylof, Martin; Ross, Svante; Thorberg, Seth-Olov

PA Astra Aktiebolag, Swed.

SO PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9914212	A1	19990325	WO 1998-SE1603	19980909
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				


10/714,577

10/27/04

DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

ZA 9807813	A	19990318	ZA 1998-7813	19980827
CA 2304037	AA	19990325	CA 1998-2304037	19980909
AU 9891932	A1	19990405	AU 1998-91932	19980909
AU 734580	B2	20010614		
BR 9812238	A	20000718	BR 1998-12238	19980909
TR 200000736	T2	20000721	TR 2000-200000736	19980909
EP 1025095	A1	20000809	EP 1998-944377	19980909
EP 1025095	B1	20031126		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 200000140	A	20010215	EE 2000-200000140	19980909
JP 2001516754	T2	20011002	JP 2000-511761	19980909
AT 255098	E	20031215	AT 1998-944377	19980909
US 6479497	B1	20021112	US 1998-171570	19981021
HR 2000000132	A1	20011231	HR 2000-132	20000309
NO 2000001402	A	20000509	NO 2000-1402	20000317
US 2003100556	A1	20030529	US 2002-285743	20021101
US 6670359	B2	20031230		
US 2004157857	A1	20040812	US 2003-714577	20031113
PRAI SE 1997-3377	A	19970918		
WO 1998-SE1603	W	19980909		
US 1998-171570	A3	19981021		
US 2002-285743	A3	20021101		
OS MARPAT 130:237475				
IT 221360-30-1P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of substituted chroman derivs. and their effects at the h5-HT1B receptor)				
RN 221360-30-1	CAPLUS			
CN 2H-1-Benzopyran-3-amine, 3,4-dihydro-5-(4-methyl-1-piperazinyl)-, (3R)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry. Rotation (+).



10/714,577

10/27/04

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

10/714,577

10/27/04

=>


Uploading C:\Stnexp4 corrupted\QUERIES\10714577i.str

L6 STRUCTURE UPLOADED

=> d 16

L6 HAS NO ANSWERS

L6 STR



G1
G1 H, Cb, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s 16

10/714,577